Ye Y, Li X, Zhu L, Yang C, Tan YW. Establishment of a risk assessment score for deep vein thrombosis after artificial liver support system treatment. World J Clin Cases 2021; 9(31): 9406-9416 [PMID: 34877276 DOI: 10.12998/wjcc.v9.i31.9406]
Corresponding Author of This Article
You-Wen Tan, MD, Chief Doctor, Professor, Department of Hepatology, The Third Hospital of Zhenjiang Affiliated Jiangsu University, No. 300 Danjiamen, Runzhou District, Zhenjiang 212000, Jiangsu Province, China. tyw915@sina.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Retrospective Cohort Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Nov 6, 2021; 9(31): 9406-9416 Published online Nov 6, 2021. doi: 10.12998/wjcc.v9.i31.9406
Table 1 Comparison of demographic and clinical characteristics for deep venous thrombosis after artificial liver support system in Stage I
Parameters
DVT (n = 12)
No-DVT (n = 220)
Statistics
P value
Gender, n (%)
Man
7 (58.3)
165 (75)
1.649
0.306
Woman
5 (41.7)
55 (25)
Age (yrs), n (%)
< 40
2 (18.2)
51 (28.7)
7.17
0.027
< 60, ≥ 40
4 (36.4)
101 (56.7)
≥ 60
5 (45.5)
26 (14.6)
Mean arterial pressure (mmHg), mean ± SD
83.45 ± 14.47
84.11 ± 13.26
0.768
0.707
Fasting plasma glucose (mmol/L), mean ± SD
5.43 ± 1.51
5.41 ± 1.65
0.332
0.542
Smoke, n (%)
No
7 (58.3)
142 (64.5)
0.197
0.759
Yes
5 (41.7)
78 (35.5)
Catheterization mode, n (%)
Jugular vein
0 (0)
72 (30)
5.09
0.022
Femoral vein
12 (100)
168 (70)
Times of successful catheterization, n (%)
One
3 (25)
151 (71.9)
16.669
0
Two
4 (33.3)
41 (19.5)
Three and more
5 (21.7)
18 (8.6)
Heparin therapy, n (%)
No
3 (25)
56 (25.5)
0.01
0.971
Yes
9 (75)
164 (74.5)
Procoagulant therapy, n (%)
No
8 (67.7)
164 (74.5)
0.368
0.513
Yes
4 (33.3)
56 (125.5)
Etiology, n (%)
Virus hepatitis
9 (75)
133 (60.5)
1.028
0.795
Drug injury
1 (8.3)
29 (13.2)
Autoimmune liver disease
1 (8.3)
24 (11.8)
Others
1 (8.3)
32 (14.5)
ALSS times, n (%)
< 3
3 (25)
61 (27.7)
7.344
0.025
≥ 3, < 5
5 (21.7)
139 (63.2)
≥ 5
4 (33.3)
20 (9.1)
Activity status, n (%)
Free activities
0 (0)
23 (10.5)
10.773
0.013
Less than 4 h/d
2 (16.7)
89 (40.5)
Less than 1 h/d
4 (33.3)
74 (33.6)
Strict bed rest
6 (50.0)
32 (15.5)
Ascites status, n (%)
No
3 (25)
67 (28.1)
0.923
0.82
Mild
4 (33.3)
79 (37.6)
Moderate
3 (25)
56 (25.7)
Severe
2 (16.7)
19 (8.6)
Bleeding, n (%)
No
8 (67.7)
153 (69.5)
0.436
0.833
Yes
4 (33.3)
67 (30.5)
Hepatic encephalopathy, n (%)
No
6 (54.5)
148 (67.3)
1.933
0.385
I-II
4 (33.3)
55 (25.0)
III-IV
2 (17.5)
17 (7.7)
Infection, n (%)
No
4 (33.3)
144 (65.5)
5.083
0.031
Yes
8 (67.7)
76 (34.5)
Complicated by other serious diseases, n (%)
No
8 (67.7)
174 (79.1)
1.039
0.294
Yes
4 (33.3)
46 (20.9)
Body mass index (kg/m2), n (%)
< 23
2 (20.0)
77 (35)
2.262
0.332
≥ 23, < 25
4(40.0)
97 (44.1)
≥ 25
4 (40.0)
46 (20.9)
Platelet count (109/L), n (%)
< 100
3 (25)
99 (45)
2.258
0.277
≥ 100, < 300
8 (66.7)
95 (43.2)
≥ 300
1 (8.3)
16 (11.8)
Total bilirubin (μmol/L), mean ± SD
234.45 ± 155.12
231.65 ± 132.86
1.476
0.583
Alanine aminotransferase (U/L), mean ± SD
256.82 ± 243.455
294.65 ± 341.36
1.20·
0.578
D-dimer (ng/mL), n (%)
< 200
1 (8.3)
88 (40)
12.232
0.002
≥ 200, < 500
3 (25.9)
82 (37.3)
≥ 500
8 (66.7)
50 (22.7)
Fibrinogen (g/L), mean ± SD
1.25 ± 0.43
1.33 ± 1.12
2.554
0.212
International normalized ratio, n (%)
< 1.5
0 (0)
0 (0)
0.215
0.767
≥ 1.5, < 2
6 (54.5)
125 (56.8)
≥ 2
6 (45.5)
85 (43.2)
Table 2 Logistic regression analysis of influencing factors of deep venous thrombosis after artificial liver support system
Parameters
β
Wald χ2
OR
95%CI
P value
Age (yrs)
0.454
5.776
1.734
1.034-2.543
0.01
< 40
1
< 60, ≥ 40
0.034
2.765
1.114
0.324-3.654
0.95
≥ 60
3.354
8.234
1.886
1.154-4.853
0.005
Catheterization mode
Jugular vein
1
Femoral vein
0.068
0.976
0.645
0.550-1.655
0.121
ALSS times
1.63
1.424
0.257-1.667
0.223
< 3
1
≥ 3, < 5
0.354
0.564
0.454
0.416-2.534
0.531
≥ 5
0.243
0.486
1.321
1.013-6.534
0.615
Times of successful catheterization
One
1
Two
0.672
1.534
0.674
0.056-1.132
0.242
Three and more
1.246
6.435
1.667
1.005-3.235
0.005
Activity status
Free activities
1
Less than 4 h/d
0.54
1.004
1.028
0.062-1.002
0.972
Less than 1 h/d
0.764
0.172
1.565
0.999-1.504
0.128
Strict bed rest
1.547
11.074
3.049
1.744-8.414
< 0.001
D-dimer (ng/mL)
< 200
1
≥ 200, < 500
1.322
1.653
1.674
1.056-2.232
0.064
≥ 500
2.115
12.231
5.532
1.404-12.133
< 0.001
Infection
No
1
Yes
2.431
16.236
2.426
1.003-89.342
0.008
Table 3 Establishment of risk assessment score for deep venous thrombosis after artificial liver support system
Indicators
Score
D-dimer
3
Infection
2
Strict bed rest
2
Age (≥ 60 yrs)
2
Times of successful catheterization (≥ 3)
1
Table 4 Comparison of demographic and clinical characteristics for deep venous thrombosis after artificial liver support system stage II, n (%)
Parameters
DVT (n = 14)
No-DVT (n = 199)
Statistics
P value
Gender
Man
9 (64.3)
165 (82.9)
3.035
0.082
Woman
5 (35.7)
34 (17.1)
Age (yrs)
< 40
2 (16.7)
51 (25.6)
11.004
0.004
< 60, ≥ 40
2 (16.7)
101 (50.8)
≥ 60
8 (66.7)
47 (23.6)
Catheterization mode
Jugular vein
2 (14.3)
51 (25.6)
0.903
0.343
Femoral vein
12 (85.7)
148 (74.4)
Times of successful catheterization
One
3 (21.4)
120 (60.3)
13.742
0.001
Two
4 (28.6)
51 (25.6)
Three and more
7 (50.0)
28 (14.1)
ALSS times
< 3
4 (28.6)
61 (30.7)
9.207
0.01
≥ 3, < 5
5 (35.7)
119 (50.8)
≥ 5
5 (35.7)
19 (9.5)
Activity status
Free activities
0 (0)
23 (11.6)
11.761
0.008
Less than 4 h/d
4 (28.6)
69 (34.7)
Less than 1 h/d
4 (28.6)
84 (42.6)
Strict bed rest
6 (42.9)
23 (11.6)
Infection
No
4 (28.6)
114 (57.6)
4.365
0.037
Yes
10 (71.4)
85 (42.4)
D-dimer (ng/mL)
< 200
1 (7.1)
65 (32.7)
14.84
0.001
≥ 200, < 500
4 (28.6)
94 (47.2)
≥ 500
9 (64.3)
40 (20.1)
Citation: Ye Y, Li X, Zhu L, Yang C, Tan YW. Establishment of a risk assessment score for deep vein thrombosis after artificial liver support system treatment. World J Clin Cases 2021; 9(31): 9406-9416